Jagsonpal Pharmaceuticals Limited

rs,

21, 2022 To, The Department of Corporate Services- Listing BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400 001 To, The Department of Corporate Services- Listing National Stock E

INR 188

ticals at a Glance Founded in 1964, track record of ~47 years FY21 Revenue from Operations(1): INR 188cr. FY21 EBITDA(1): INR19cr. FY21 PAT: INR17cr. 70%+ Focus on Gynaec and Orthopedic Therapy Segme

INR19

d in 1964, track record of ~47 years FY21 Revenue from Operations(1): INR 188cr. FY21 EBITDA(1): INR19cr. FY21 PAT: INR17cr. 70%+ Focus on Gynaec and Orthopedic Therapy Segments(2) Field force of 60

INR17

ecord of ~47 years FY21 Revenue from Operations(1): INR 188cr. FY21 EBITDA(1): INR19cr. FY21 PAT: INR17cr. 70%+ Focus on Gynaec and Orthopedic Therapy Segments(2) Field force of 600+ personnel 5+ B

70%

47 years FY21 Revenue from Operations(1): INR 188cr. FY21 EBITDA(1): INR19cr. FY21 PAT: INR17cr. 70%+ Focus on Gynaec and Orthopedic Therapy Segments(2) Field force of 600+ personnel 5+ Brands a

10%

ld force of 600+ personnel 5+ Brands among top 10 brands with #1/#2 Market Positions Generics 10% API 6% Shovacare Division 3% Naari Division 7% Others 4% Revenue from Operations (FY21) Pha

6%

of 600+ personnel 5+ Brands among top 10 brands with #1/#2 Market Positions Generics 10% API 6% Shovacare Division 3% Naari Division 7% Others 4% Revenue from Operations (FY21) Pharma Div

3%

Brands among top 10 brands with #1/#2 Market Positions Generics 10% API 6% Shovacare Division 3% Naari Division 7% Others 4% Revenue from Operations (FY21) Pharma Division 71% Footnote: (1

7%

0 brands with #1/#2 Market Positions Generics 10% API 6% Shovacare Division 3% Naari Division 7% Others 4% Revenue from Operations (FY21) Pharma Division 71% Footnote: (1) Excludes Other In

rs 4

with #1/#2 Market Positions Generics 10% API 6% Shovacare Division 3% Naari Division 7% Others 4% Revenue from Operations (FY21) Pharma Division 71% Footnote: (1) Excludes Other Income; (2)

71%

care Division 3% Naari Division 7% Others 4% Revenue from Operations (FY21) Pharma Division 71% Footnote: (1) Excludes Other Income; (2) Denominator is Revenue from Operations less Generics, API

88%

Naari Division Shovacare Division Revenue contribution within formulations business (FY21)(1) 88% 8% 4% Footnote: (1) Denominator is Revenue from Operations excluding Generics, API and Others Di